Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224438 · ClinicalTrials.gov registry record · Phase 2
Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea
A Phase 2 study of Hypogonadotropic Hypogonadism and Hypothalamic Amenorrhea, sponsored by Stephanie B. Seminara, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07224438 is a Phase 2 study of Hypogonadotropic Hypogonadism and Hypothalamic Amenorrhea that is actively recruiting participants, run by Stephanie B. Seminara, MD. The registered enrollment target is 20 participants, below the 123-participant average among 6 other Hypogonadotropic Hypogonadism trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07224438, a Phase 2 study of Hypogonadotropic Hypogonadism and Hypothalamic Amenorrhea, is actively recruiting participants, sponsored by Stephanie B. Seminara, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.
Conditions Studied
Interventions
- DRUG kisspeptin 112-121
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2030-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224438
The ClinicalTrials.gov registry entry for NCT07224438 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 6 other Hypogonadotropic Hypogonadism trials with a reported enrollment target (84% lower). The listed sponsor is Stephanie B. Seminara, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypogonadotropic Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which kisspeptin 112-121 is the first listed.
NCT07224438 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07224438 about?
NCT07224438 is a clinical study titled "Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea". The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin ...
What is the current status of trial NCT07224438?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-12-09. Estimated completion is 2030-05.
What conditions does trial NCT07224438 study?
This clinical trial studies the following conditions: Hypogonadotropic Hypogonadism, Hypothalamic Amenorrhea.
What interventions are being tested in trial NCT07224438?
The interventions under investigation include: kisspeptin 112-121 (DRUG).
Who is sponsoring clinical trial NCT07224438?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224438 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadotropic Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Kisspeptin Administration Subcutaneously to Patients With IHH
RECRUITING · Phase 2
-
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
RECRUITING
-
The Molecular Basis of Inherited Reproductive Disorders
RECRUITING
-
Effect of Intranasal Insulin on LH Concentrations in Man
COMPLETED · Phase 1
-
Opioid Antagonism in Hypogonadotropic Hypogonadism
COMPLETED · Phase 1
-
Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions
COMPLETED · Phase 3
Explore more on PlainTrial
Hypogonadotropic Hypogonadism
All registered trials for this condition
Hypothalamic Amenorrhea
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.